Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA242103
Max Phase: Preclinical
Molecular Formula: C9H11N3O2S
Molecular Weight: 225.27
Molecule Type: Small molecule
Associated Items:
ID: ALA242103
Max Phase: Preclinical
Molecular Formula: C9H11N3O2S
Molecular Weight: 225.27
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: COc1ccc(/C=N/NC(N)=S)cc1O
Standard InChI: InChI=1S/C9H11N3O2S/c1-14-8-3-2-6(4-7(8)13)5-11-12-9(10)15/h2-5,13H,1H3,(H3,10,12,15)/b11-5+
Standard InChI Key: ARINKVDYBABITQ-VZUCSPMQSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 225.27 | Molecular Weight (Monoisotopic): 225.0572 | AlogP: 0.57 | #Rotatable Bonds: 3 |
Polar Surface Area: 79.87 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 9.62 | CX Basic pKa: 2.15 | CX LogP: 1.20 | CX LogD: 1.20 |
Aromatic Rings: 1 | Heavy Atoms: 15 | QED Weighted: 0.40 | Np Likeness Score: -1.05 |
1. Du X, Guo C, Hansell E, Doyle PS, Caffrey CR, Holler TP, McKerrow JH, Cohen FE.. (2002) Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruzain., 45 (13): [PMID:12061873] [10.1021/jm010459j] |
2. Xue CB, Zhang L, Luo WC, Xie XY, Jiang L, Xiao T.. (2007) 3D-QSAR and molecular docking studies of benzaldehyde thiosemicarbazone, benzaldehyde, benzoic acid, and their derivatives as phenoloxidase inhibitors., 15 (5): [PMID:17258462] [10.1016/j.bmc.2006.12.038] |
3. Ferreira FB, Pereira TM, Souza DLN, Lopes DS, Freitas V, Ávila VMR, Kümmerle AE, Sant'Anna CMR.. (2017) Structure-Based Discovery of Thiosemicarbazone Metalloproteinase Inhibitors for Hemorrhage Treatment in Snakebites., 8 (11): [PMID:29152044] [10.1021/acsmedchemlett.7b00186] |
4. Hałdys K, Latajka R.. (2019) Thiosemicarbazones with tyrosinase inhibitory activity., 10 (3): [PMID:31015905] [10.1039/C9MD00005D] |
5. Guo C,Wang L,Li X,Wang S,Yu X,Xu K,Zhao Y,Luo J,Li X,Jiang B,Shi D. (2019) Discovery of Novel Bromophenol-Thiosemicarbazone Hybrids as Potent Selective Inhibitors of Poly(ADP-ribose) Polymerase-1 (PARP-1) for Use in Cancer., 62 (6.0): [PMID:30844273] [10.1021/acs.jmedchem.8b01946] |
Source(1):